illustration 1

SpotitEarly BRCA

SpotitEarly BRCA is a molecular test used to identify patients with germline BRCA1/2 mutations. The test aims to identify 3 inherited mutations in BRCA 1 and 2, common in the Ashkenazi Jews, known to cause, with high prevalence, breast, and ovarian cancer.

This method is well established and widely used for population screening in health care providers and hospitals in Israel, and Jewish communities around the world.

Updated breast cancer professional guidelines recommend germline testing for every breast cancer patient.

The results of each test component, along with the interpretation of variant(s) identified, will be delivered within 2 weeks

illustration 2

How to test with SpotitEarly BRCA test?

A saliva specimens collected using a swab tube is submitted to SpotitEarly as part of the test kit.

Find out more about our SpotitEarly BRCA test